{
  "abstract": "Introduction: The cerebellum plays a crucial role in cognitive processing and thus presents a promising therapeutic target for Alzheimer’s disease (AD). This trial aims to evaluate the efficacy and safety of long-term, neuronavigated cerebellar intermittent theta burst stimulation (iTBS) in patients with AD.\n\nMethods and analysis: The ACT-AD trial is a multicenter, randomized, double-blind, sham-controlled study involving 100 participants with mild-to-moderate AD across 4 centers in China. Participants will be randomized to receive either cerebellar iTBS or sham stimulation for 4 weeks (daily sessions), followed by 8 weeks of weekly maintenance sessions. The primary outcome is the change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score from baseline to week 12. Secondary outcomes include additional clinical scales. Exploratory outcomes include electroencephalogram (EEG), blood biomarkers and magnetic resonance imaging (MRI). Statistical analysis will follow intention-to-treat principles using mixed models for repeated measures (MMRM).\n\nDiscussion: The ACT-AD trial will assess the efficacy and safety of long-term, neuronavigated cerebellar iTBS in treating patients with mild-to-moderate AD.\n\nTrial registration: ClinicalTrials.gov, NCT06669182. Registered on 31 October 2024.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 15,
  "authors": [
    {
      "name": "Xin Zhang"
    },
    {
      "name": "Wen Li"
    },
    {
      "name": "Zhongqing Sun"
    },
    {
      "name": "Xiaomu Wang"
    },
    {
      "name": "Changgeng Song"
    },
    {
      "name": "Xiaorui Wang"
    },
    {
      "name": "Yinuo Niu"
    },
    {
      "name": "Dong Wei"
    },
    {
      "name": "Wei Zhang"
    },
    {
      "name": "Gejuan Zhang"
    },
    {
      "name": "Bei Zhang"
    },
    {
      "name": "Ling Wang"
    },
    {
      "name": "Zhirong Liu"
    },
    {
      "name": "Jingjing Zhao"
    },
    {
      "name": "Wen Jiang",
      "orcid": "0000-0003-0612-2917"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/45qx3sj8pxzvh.bib",
  "cited_by": 0,
  "doi": "10.1186/s13063-026-10009-w",
  "fulltext_url": null,
  "id": "45qx3sj8pxzvh",
  "issns": [
    "1745-6215"
  ],
  "landing_url": "https://link.springer.com/10.1186/s13063-026-10009-w",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2808|Transcranial Magnetic Stimulation Studies"
    ]
  ],
  "openalex": "W7220900319",
  "pdf_url": "https://link.springer.com/content/pdf/10.1186/s13063-026-10009-w.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-09",
  "publisher": "Springer Science and Business Media LLC",
  "ris": "https://research.draconitic.com/paper/45qx3sj8pxzvh.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:30Z",
      "native_id": "10.1186/s13063-026-10009-w",
      "source": "crossref",
      "url": "https://link.springer.com/10.1186/s13063-026-10009-w"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2808|Transcranial Magnetic Stimulation Studies",
      "subfield": "neurology"
    }
  ],
  "title": "Advantage of cerebellar intermittent theta-burst stimulation in Alzheimer's disease (ACT-AD): study protocol for a multicenter, randomized, double-blind, sham-controlled trial",
  "title_text": "Advantage of cerebellar intermittent theta-burst stimulation in Alzheimer's disease (ACT-AD): study protocol for a multicenter, randomized, double-blind, sham-controlled trial",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:30Z",
  "url": "https://research.draconitic.com/paper/45qx3sj8pxzvh",
  "venue": "Trials",
  "versions": []
}